ReviewCancers2024
Hematologic Toxicity and Bone Marrow-Sparing Strategies in Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Hematological Toxicity and Bone Marrow Dose-Volume Effects in Chemotherapy-Naïve Patients Treated With Whole Pelvic and Para-aortic Lymph Node Radiation Therapy For Pathologic Pelvic Lymph Node-Positive Prostate Cancer.Advances in radiation oncology · 2026Article
- Comment on: "Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy."Clinical and translational radiation oncology · 2026Article
- Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- Potential normal tissue sparing in vulvar cancer using intensity modulated proton therapy versus volumetric modulated arc therapy.Physics and imaging in radiation oncology · 2026Article
- Three-year post-recurrence survival outcome by leukopenia grade 2+ during systemic chemotherapy in recurrent cervical cancer.Obstetrics & gynecology science · 2026Article
- Article
- Peripheral blood lymphocyte and eosinophil dynamics with chemotherapy and pembrolizumab in cervical cancer.International journal of clinical oncology · 2026Article
- Article
- Article
- Bone Marrow-Sparing Pelvic Radiotherapy: Clinical Evidence, Dosimetric Constraints, and Clinical Outcomes.Cureus · 2026Review
- A quantitative treatment assessment for optimizing combined virotherapy-chemotherapy regimens against HPV-induced cervical cancer.PloS one · 2026Article
- Pegylated recombinant human granulocyte colony-stimulating factor enhances radiotherapy completion and safety in concurrent chemoradiotherapy for cervical cancer: a retrospective analysis.Frontiers in oncology · 2025Article
- Feasibility study of U-Net-based automatic segmentation of pelvic bone marrow for postoperative radiotherapy in cervical cancer.Frontiers in oncology · 2025Article
- Combined clinical and MRI-based radiomics model for predicting acute hematologic toxicity in gynecologic cancer radiotherapy.Frontiers in oncology · 2025Article
- Predictive value of bowel dose-volume for severe radiation-induced lymphopenia and survival in cervical cancer.Frontiers in immunology · 2024Article
- Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard treatment for locally advanced cervical cancer typically includes concomitant chemoradiation, a regimen known to induce severe hematologic toxicity (HT). Particularly, pelvic bone marrow dose exposure has been identified as a contributing factor to this hematologic toxicity. Chemotherapy further increases bone marrow suppression, often necessitating treatment interruptions or dose reductions. A systematic search for original articles published between 1 January 2006 and 7 January 2024 that reported on chemoradiotherapy for locally advanced cervical cancer and hematologic toxicities was conducted. Twenty-four articles comprising 1539 patients were included in the final analysis. HT of grade 2 and higher was observed across all studies and frequently exceeded 50%. When correlating active pelvic bone marrow and HT, significant correlations were found for volumes between 10 and 45 Gy and HT of grade 3 and higher. Several dose recommendations for pelvic bone and pelvic bone marrow sparing to reduce HT were established, including V10 < 90-95%, V20 < 65-86.6% and V40 < 22.8-40%. Applying dose constraints to the pelvic bone/bone marrow is a promising approach for reducing HT, and thus reliable implementation of therapy. However, prospective randomized controlled trials are needed to define precise dose constraints and optimize clinical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.